

Integra LifeSciences Names James Oti Senior Vice President of Global Operations

PLAINSBORO, N.J., Jan 11, 2008 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the appointment of James A. Oti as Senior Vice President of Global Operations, effective immediately.

Mr. Oti brings to Integra more than 14 years of medical device experience in operations and production management, emerging technologies, engineering, global sourcing and logistics. As Senior Vice President of Global Operations, Mr. Oti will be responsible for global manufacturing activities, planning, repair and service.

"We are delighted that Jim is joining the Integra team," said Gerard Carlozzi, "He brings a wealth of industry experience that will be invaluable as we continue to focus on delivering high quality, cost effective products to our customers."

Mr. Oti joins Integra following 14 years at Johnson & Johnson (J&J), where he held a number of positions of growing responsibility, most recently as Director of J&J's Worldwide Operations & Advanced Manufacturing. He was also responsible for J&J's \$500 million Raynham facility and the worldwide advanced manufacturing strategy for the \$4 billion DePuy franchise. During his tenure at J&J, Mr. Oti created a unified global operations strategy that was driven by operational competitiveness, new product development and new product launches. Prior to joining J&J, Mr. Oti held engineering and program management positions with TRW Aircraft Component Group/PCC Airfoils, Inc.

"I am very impressed with Integra's growth and its commitment to quality and the customer. I am excited to be part of a team that continues to demonstrate excellent corporate leadership," said Mr. Oti.

Mr. Oti received undergraduate and graduate degrees in Engineering from Western Michigan University and Case Western Reserve University respectively.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.lntegra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. The economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART - G

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

```
Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President,
Chief Administrative Officer, Acting Chief
Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Gianna Sabella, Public Relations Manager
(609) 936-2389
gsabella@integra-LS.com
```

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.